Skip to main content
Erschienen in:

19.03.2021 | Clinical trial

A propensity score-matched comparison of recurrence outcomes after immediate implant vs autologous flap reconstruction in patients receiving neoadjuvant chemotherapy for breast cancer

verfasst von: Zhen-Yu Wu, Hyun Ho Han, Hee Jeong Kim, Jong Won Lee, Il Yong Chung, Jisun Kim, Sae Byul Lee, Byung-Ho Son, Jin Sup Eom, Jae Ho Jung, Sung- Bae Kim, Gyungyub Gong, Hak Hee Kim, Sei -Hyun Ahn, BeomSeok Ko

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We compared oncologic outcomes between breast cancer patients who underwent immediate implant-based breast reconstruction (IBBR) and those who underwent autologous flap reconstruction (AFR) after neoadjuvant chemotherapy (NACT).

Methods

The study group comprised 536 patients with primary breast cancer who underwent NACT followed by immediate IBBR or AFR. After propensity score matching, 138 patients in the IBBR group and 276 patients in the AFR group were selected for comparisons of locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and breast cancer-specific survival (BCSS).

Results

No significant differences were observed between the matched groups in locoregional recurrence rates (IBBR vs. AFR: 12.3% vs. 12%; P = 0.915) and distant metastasis (13% vs. 17%; P = 0.293). There was also no significant difference between the groups in LRRFS (P = 0.956), DFS (P = 0.606), DMFS (P = 0.283), or BCSS (P = 0.121). The 5- and 10-year LRRFS rates were 87.6% and 85.9% in the IBBR group, and 87.7% and 86.1% in the AFR group; the 5- and 10-year DFS rates were 79% and 77.5% in the IBBR group, and 77% and 75% in the AFR group; the 5- and 10-year DMFS rates were 85.9% and 85.9% in the IBBR group, and 83.2% and 81.8% in the AFR group; and the 5- and 10-year BCSS rates were 97.8% and 91.3% in the IBBR group, and 91.8% and 86% in the AFR group, respectively.

Conclusions

In this propensity score-matched analysis of oncologic outcomes in breast cancer patients who underwent immediate reconstruction after NACT, no significant differences were observed between the IBBR and AFR groups.
Literatur
6.
Zurück zum Zitat Lee SB, Lee JW, Kim HJ et al (2018) Long-term outcomes of patients with breast cancer after nipple-sparing mastectomy/skin-sparing mastectomy followed by immediate transverse rectus abdominis musculocutaneous flap reconstruction: comparison with conventional mastectomy in a single center study. Medicine (Baltimore) 97(18):e0680. https://doi.org/10.1097/MD.0000000000010680CrossRef Lee SB, Lee JW, Kim HJ et al (2018) Long-term outcomes of patients with breast cancer after nipple-sparing mastectomy/skin-sparing mastectomy followed by immediate transverse rectus abdominis musculocutaneous flap reconstruction: comparison with conventional mastectomy in a single center study. Medicine (Baltimore) 97(18):e0680. https://​doi.​org/​10.​1097/​MD.​0000000000010680​CrossRef
11.
Zurück zum Zitat Vieira R, Ribeiro LM, Carrara GFA, Abrahão-Machado LF, Kerr LM, Nazário ACP (2019) Effectiveness and safety of implant-based breast reconstruction in locally advanced breast carcinoma: a matched case-control study. Breast Care (Basel) 14(4):200–210. https://doi.org/10.1159/000496429CrossRef Vieira R, Ribeiro LM, Carrara GFA, Abrahão-Machado LF, Kerr LM, Nazário ACP (2019) Effectiveness and safety of implant-based breast reconstruction in locally advanced breast carcinoma: a matched case-control study. Breast Care (Basel) 14(4):200–210. https://​doi.​org/​10.​1159/​000496429CrossRef
13.
Zurück zum Zitat Collett DJ, Rakhorst H, Lennox P, Magnusson M, Cooter R, Deva AK (2019) Current risk estimate of breast implant-associated anaplastic large cell lymphoma in textured breast implants. PlastReconstrSurg 143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):30S-40S. https://doi.org/10.1097/PRS.0000000000005567CrossRef Collett DJ, Rakhorst H, Lennox P, Magnusson M, Cooter R, Deva AK (2019) Current risk estimate of breast implant-associated anaplastic large cell lymphoma in textured breast implants. PlastReconstrSurg 143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):30S-40S. https://​doi.​org/​10.​1097/​PRS.​0000000000005567​CrossRef
17.
Zurück zum Zitat Amin MB, Edge S, Greene F et al (2017) AJCC cancer staging manual, 8th edn. Springer, New York, NYCrossRef Amin MB, Edge S, Greene F et al (2017) AJCC cancer staging manual, 8th edn. Springer, New York, NYCrossRef
Metadaten
Titel
A propensity score-matched comparison of recurrence outcomes after immediate implant vs autologous flap reconstruction in patients receiving neoadjuvant chemotherapy for breast cancer
verfasst von
Zhen-Yu Wu
Hyun Ho Han
Hee Jeong Kim
Jong Won Lee
Il Yong Chung
Jisun Kim
Sae Byul Lee
Byung-Ho Son
Jin Sup Eom
Jae Ho Jung
Sung- Bae Kim
Gyungyub Gong
Hak Hee Kim
Sei -Hyun Ahn
BeomSeok Ko
Publikationsdatum
19.03.2021
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-021-06114-w

Neu im Fachgebiet Onkologie

Fünf Faktoren sagen Lymphödeme nach Brustkrebs voraus

Ob nach der operativen Behandlung von Brustkrebs ein Lymphödem droht, lässt sich anhand eines Risikomodells abschätzen, das auf fünf leicht verfügbaren klinischen Parametern beruht.

Genügt die biparametrische MRT für die Prostatadiagnostik?

Die multiparametrische Magnetresonanztomografie hat einen festen Platz im Screening auf klinisch signifikante Prostatakarzinome. Ob auch ein biparametrisches Vorgehen ausreicht, ist in einer Metaanalyse untersucht worden.

Metastasiertes CRC: besser Checkpointhemmer im Doppelpack!

Die Kombination von Nivolumab plus Ipilimumab ist beim metastasierten Kolorektalkarzinom mit MSI-H- oder dMMR klar im Vorteil gegenüber einer Nivolumab-Monotherapie: Das Progressionsrisiko war damit in einer Phase-3-Studie um 38% reduziert.

Große Trinkmengen bei Blasentumoren möglicherweise von Nachteil

Beim nicht-muskelinvasiven Blasenkrebs scheint eine hohe Flüssigkeitszufuhr keinen schützenden Effekt in Bezug auf das Risiko eines Rezidivs oder einer Krankheitsprogression zu haben. Eine niederländische Studie legt sogar nahe, dass große Trinkmengen das Fortschreiten der Erkrankung begünstigen könnten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.